Hepatocyte transplantation using biodegradable matrices in ascorbic acid-deficient rats: Comparison with heterotopically transplanted liver grafts

被引:23
作者
Uyama, S [1 ]
Kaufmann, PM [1 ]
Kneser, U [1 ]
Fiegel, HC [1 ]
Pollok, JM [1 ]
Kluth, D [1 ]
Vacanti, JP [1 ]
Rogiers, X [1 ]
机构
[1] Univ Hamburg, Med Ctr, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany
关键词
D O I
10.1097/00007890-200105150-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Hepatocyte transplantation using polymeric matrices is under investigation as an alternative therapy for metabolic liver diseases. Long-term engraftment of hepatocytes in polymers has been demonstrated. However, the metabolic activity of hepatocytes in such devices has never been assessed in direct comparison with liver grafts. Methods. Hepatocyte and partial liver transplantation were evaluated in the scurvy-prone osteogenic disorder Shionogi rat model. Biodegradable poly glycolic acid matrices seeded with hepatocytes equivalent to 20% of the recipient's liver mass, or 20% liver grafts were heterotopically transplanted into ascorbic acid- (AsA) deficient recipients. Recipients of cell-free matrices or AsA-deficient liver grafts served as controls. Recipients were set on AsA-free diet after transplantation. Plasma AsA levels, AsA concentrations in liver and adrenal gland tissue, and body weight ratios were assessed and H&E histology was performed. Results. Recipients from the control groups showed symptoms of scurvy at 1 month after cessation of AsA supply, Hepatocyte transplantation and auxiliary liver transplantation prevented symptoms of scurvy and increased plasma and tissue AsA levels and body weight ratios. AsA levels in recipients of 20% liver grafts were comparable to normal control animals, Conclusions. Hepatocytes transplanted in polymeric matrices are able to compensate for liver-based metabolic deficiencies. Hepatocyte transplantation improves plasma AsA levels in AsA-deficient recipients. However, auxiliary liver grafts are superior to hepatocyte grafts in improving metabolic parameters. Further research work is needed to increase the efficiency of liver cell transplantation with regard to a clinical application.
引用
收藏
页码:1226 / 1231
页数:6
相关论文
共 42 条
[31]  
Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO
[32]  
2-C
[33]   LONG-TERM EFFECT OF INTRASPLENIC HEPATOCYTE TRANSPLANTATION IN CONGENITALLY ASCORBIC-ACID BIOSYNTHETIC ENZYME-DEFICIENT RATS [J].
ONODERA, K ;
KASAI, S ;
KATO, K ;
NAKAZAWA, F ;
MITO, M .
CELL TRANSPLANTATION, 1995, 4 :S41-S43
[34]   CELL TRANSPLANTATION IN LIVER-DIRECTED GENE-THERAPY [J].
RAPER, SE ;
WILSON, JM .
CELL TRANSPLANTATION, 1993, 2 (05) :381-400
[35]   Auxiliary liver transplantation for metabolic diseases [J].
Rela, M ;
Muiesan, P ;
Andreani, P ;
Gibbs, P ;
MieliVergani, G ;
Mowat, AP ;
Heaton, ND .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :444-445
[36]  
Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5
[37]   Cancer in immune-suppressed organ transplant recipients: Aetiology and evolution [J].
Sheil, AGR .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :2055-2057
[38]   LIVER-DISEASE IN ALPHA1-ANTITRYPSIN DEFICIENCY DETECTED BY SCREENING OF 200,000 INFANTS [J].
SVEGER, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (24) :1316-1321
[39]  
TAKEDA T, 1995, TRANSPLANT P, V27, P635
[40]  
UYAMA S, 1993, TRANSPLANTATION, V55, P932